An expanded biomarker panel for the detection of prostate cancer from urine DNA.

ABSTRACT:

Background

Prostate cancer diagnosis using the PSA test remains controversial because of overdiagnosis and overtreatment of potentially indolent cancers. There remains a need to increase the diagnostic lead time and to target treatment to patients with significant disease. One possible approach to overcome the limitations of PSA is to screen men for the molecular signature of early PCA, monitor the rate of disease progression and target treatment to patients who are likely to benefit from it. Such an approach requires a large panel of markers that define a molecular clock for PCA. We recently developed a panel of 19 markers for the non-invasive detection of PCA from urine DNA. It raised the possibility that additional methylation markers could be successfully analyzed from urine DN

SUBMITTER: Brikun I 

PROVIDER: S-EPMC6598372 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature